FY2024 Earnings Estimate for CVE:APM Issued By Desjardins

Andean Precious Metals Corp. (CVE:APM) – Desjardins cut their FY2024 earnings per share estimates for shares of Andean Precious Metals in a report issued on Monday, November 11th. Desjardins analyst A. Carson now anticipates that the company will earn $0.15 per share for the year, down from their prior forecast of $0.20. Desjardins has a “Moderate Buy” rating on the stock. The consensus estimate for Andean Precious Metals’ current full-year earnings is $0.38 per share.

Andean Precious Metals (CVE:APM) last posted its quarterly earnings data on Tuesday, August 13th. The company reported C$0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$0.08. Andean Precious Metals had a return on equity of 41.08% and a net margin of 23.75%. The firm had revenue of C$95.47 million during the quarter.

Andean Precious Metals Price Performance

APM opened at C$1.10 on Wednesday. The stock has a market cap of C$164.30 million, a PE ratio of 3.03 and a beta of 1.22. Andean Precious Metals has a 12-month low of C$0.55 and a 12-month high of C$2.18. The business has a 50-day moving average price of C$1.51.

Insiders Place Their Bets

In other Andean Precious Metals news, insider 2176423 Ontario Ltd. acquired 700,000 shares of the company’s stock in a transaction on Tuesday, September 24th. The stock was acquired at an average price of C$1.36 per share, for a total transaction of C$952,000.00. In the last 90 days, insiders acquired 1,202,800 shares of company stock worth $1,607,032. 69.37% of the stock is currently owned by company insiders.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.